









Markets
/
Stocks
/
nasdaq-prok
/

ProKidney Corp

PROK

1.870USD

+0.140+8.09%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

254.28MMarket Cap

LossP/E TTM



ProKidney Corp

1.870

+0.140+8.09%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ProKidney Corp

Currency: USD Updated: 2026-02-06

Key Insights

ProKidney Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 160 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.71.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ProKidney Corp's Score

Industry at a Glance

Industry Ranking

160 / 392

Overall Ranking

307 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

ProKidney Corp Highlights

StrengthsRisks

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Growing

The company is in a growing phase, with the latest annual income totaling USD 76.00K.

Fairly Valued

The company’s latest PE is -3.41, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 41.07M shares, decreasing 6.40% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 10.21K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.16.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

6.714

Target Price

+288.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ProKidney Corp is 6.37, ranking 261 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.37

Change



Financials

8.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.29

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.18

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ProKidney Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ProKidney Corp is 6.85, ranking 212 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.41, which is -74.98% below the recent high of -0.85 and -550.08% above the recent low of -22.16.

Score

Industry at a Glance

Previous score

6.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 160/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of ProKidney Corp is 7.56, ranking 282 out of 392 in the Biotechnology & Medical Research industry. The average price target is 6.50, with a high of 10.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.56

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

6.714

Target Price

+288.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

ProKidney Corp

PROK

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ProKidney Corp is 5.43, ranking 316 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.27 and the support level at 1.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.28

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.064

Sell

RSI(14)

38.273

Neutral

STOCH(KDJ)(9,3,3)

21.881

Neutral

ATR(14)

0.147

Low Volatility

CCI(14)

-143.727

Sell

Williams %R

72.727

Sell

TRIX(12,20)

-0.648

Sell

StochRSI(14)

76.014

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.914

Sell

MA10

2.013

Sell

MA20

2.124

Sell

MA50

2.231

Sell

MA100

2.510

Sell

MA200

2.151

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ProKidney Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 29.01%, representing a quarter-over-quarter increase of 1.47%. The largest institutional shareholder is The Vanguard, holding a total of 1.65M shares, representing 1.16% of shares outstanding, with 71.06% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tolerantia LLC

22.62M

Suvretta Capital Management, LLC

12.34M

Control Empresarial de Capitales, S.A. de C.V.

10.72M

+27.04%

Morgan Stanley Investment Management Inc. (US)

6.41M

+12.24%

BlackRock Mexico Operadora SA de CV SOFI

3.43M

Operadora de Fondos GBM S.A.B. de C.V.

2.45M

Bleichroeder LP

2.00M

Millennium Management LLC

1.96M

The Vanguard Group, Inc.

Star Investors

1.56M

-0.24%

Culleton (Bruce)

1.54M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ProKidney Corp is 3.33, ranking 152 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.84. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.